
    
      Eligible patients who agree to take part in the study will receive oral dosages of
      Thalidomide at 200mg/day to start, with dosage gradually increasing up to a maximum of
      1200mg/day. This will be taken in combination with:

      5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.

      Interferon-Î±, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks.

      Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.

      Treatment will be followed by 2 weeks of rest then repeated.
    
  